系统评价 2 型糖尿病药物的试验纳入时间和频率与试验特征相关。

The timing and frequency of trial inclusion in systematic reviews of type 2 diabetes drugs was associated with trial characteristics.

机构信息

Centre for Health Informatics, Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.

Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.

出版信息

J Clin Epidemiol. 2019 May;109:62-69. doi: 10.1016/j.jclinepi.2019.01.009. Epub 2019 Jan 30.

DOI:10.1016/j.jclinepi.2019.01.009

PMID:30708175

Abstract

OBJECTIVE

To determine whether certain trial characteristics are associated with faster or more frequent inclusion in systematic reviews for drug interventions in type 2 diabetes.

STUDY DESIGN AND SETTING

We examined trials included in systematic reviews published between January 1, 2007 and January 1, 2017. Primary outcomes were time between trial publication and first inclusion in a systematic review and frequency of inclusion in systematic reviews over the study period. Multivariable Cox proportional hazards and regression models quantified associations with funding source, number of participants, trial conclusion, and journal impact factor.

RESULTS

Among 668 trials, the median time to inclusion was 76.1 weeks. Time to inclusion was shorter for trials with industry funding (hazard ratio [HR] 1.39; 95% confidence interval [CI] 1.13-1.71), more participants (HR 1.26; 95% CI 1.17-1.36), and published in higher impact factor journals (HR 1.28; 95% CI 1.14-1.45). The median frequency of inclusion was three. Frequency of inclusion was greater for trials with industry funding (relative risk [RR] 2.36; 95% CI 2.11-2.64), more participants (RR 1.51; 95% CI 1.47-1.55), positive conclusions (RR 1.89; 95% CI 1.68-2.13), and published in higher impact factor journals (RR 1.13; 95% CI 1.08-1.18).

CONCLUSION

Certain trial characteristics are associated with faster or more frequent trial inclusion in systematic reviews of type 2 diabetes.

摘要

目的

确定某些试验特征是否与 2 型糖尿病药物干预的系统评价更快或更频繁纳入相关。

研究设计和设置

我们检查了 2007 年 1 月 1 日至 2017 年 1 月 1 日期间发表的系统评价中纳入的试验。主要结局是从试验发表到首次纳入系统评价的时间以及研究期间系统评价纳入的频率。多变量 Cox 比例风险和回归模型量化了与资金来源、参与者数量、试验结论和期刊影响因子的关联。

结果

在 668 项试验中，纳入的中位时间为 76.1 周。具有行业资助的试验纳入时间更短（风险比 [HR] 1.39；95%置信区间 [CI] 1.13-1.71）、参与者更多（HR 1.26；95% CI 1.17-1.36）、发表在更高影响因子期刊的试验纳入时间也更短（HR 1.28；95% CI 1.14-1.45）。纳入的中位频率为 3 次。具有行业资助的试验纳入频率更高（相对风险 [RR] 2.36；95% CI 2.11-2.64）、参与者更多（RR 1.51；95% CI 1.47-1.55）、阳性结论（RR 1.89；95% CI 1.68-2.13）、发表在更高影响因子期刊的试验纳入频率也更高（RR 1.13；95% CI 1.08-1.18）。